Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0J1WO
|
||||
| Former ID |
DCL000548
|
||||
| Drug Name |
ISIS 113715
|
||||
| Drug Type |
Antisense drug
|
||||
| Indication | Type 2 diabetes [ICD9: 250; ICD10:E11] | Phase 2 | [536259] | ||
| Therapeutic Class |
Antisense
|
||||
| Company |
ISIS
|
||||
| Target and Pathway | |||||
| Target(s) | mRNA of Protein tyrosine phosphatase-1B | Target Info | [536259], [551054] | ||
| KEGG Pathway | Adherens junction | ||||
| Insulin signaling pathway | |||||
| NetPath Pathway | FSH Signaling Pathway | ||||
| PANTHER Pathway | Cadherin signaling pathway | ||||
| Pathway Interaction Database | Insulin Pathway | ||||
| Signaling events mediated by Hepatocyte Growth Factor Receptor (c-Met) | |||||
| Signaling events mediated by PTP1B | |||||
| Calcineurin-regulated NFAT-dependent transcription in lymphocytes | |||||
| Signaling events mediated by TCPTP | |||||
| IGF1 pathway | |||||
| EGF receptor (ErbB1) signaling pathway | |||||
| Posttranslational regulation of adherens junction stability and dissassembly | |||||
| PDGFR-beta signaling pathway | |||||
| N-cadherin signaling events | |||||
| References | |||||
| Ref 536259 | Lack of pharmacokinetic interaction for ISIS 113715, a 2'-0-methoxyethyl modified antisense oligonucleotide targeting protein tyrosine phosphatase 1B messenger RNA, with oral antidiabetic compounds metformin, glipizide or rosiglitazone. Clin Pharmacokinet. 2006;45(8):789-801. | ||||
| Ref 551054 | Clinical pipeline report, company report or official report of ISIS Pharmaceuticals (2009). | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.